Loading
TherapeuticsMD, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 29 Dec 2025.
TherapeuticsMD, Inc.: what insiders have been doing
This page follows insider dealings at TherapeuticsMD, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 1 filing came from 1 insider.
Not one open-market sale was filed. On the buying side, 1 insider reported 1 purchase totalling €12k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a purchase of €12k by Thompson Tommy G, published on 29 December 2025. Among those who bought: 1 senior executive.
The clock since the last published purchase (29 December 2025) now reads 293 days.
Across the 5,816 companies tracked on its exchange, the median is 19 filings; at 1 filing, this issuer sits below that mark. Since 2021, the database holds 18 purchases and 2 sales by insiders of the company. For the fiscal year to 31 December 2025, the annual 10-K/A puts revenue at 3.0 m USD and net income at -569,000 USD.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
61
Thresholds
n/a
Buy Volume
€18M
18 ops. · all time
Sell Volume
€19,711
2 ops. · all time
Who traded when
BuySaleMarlan D. Walker2 buys
Tommy G. Thompson2 buys
Since the insiders bought
- +21.3%Entry US$1.64 · Close at T+90 US$1.99
- +110.1%Entry US$0.99 · Close at T+365 US$2.08
- -41.7%Entry US$1.92 · Close at T+365 US$1.12
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,249 of 24,148 companies
43.3
score / 100
Value53
Quality34
FCF yld10%
Earn yld-2.4%
EV/EBITDA·
ROE0.3%
Gross mgn43%
Net mgn-19%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.09
Analyst consensus
Income statement
RevenueUS$3M
Gross profitUS$1.3M43% margin
EBITDA-US$3M-100% margin
Net income-US$569k5.3% margin
Valuation
PER (trailing)206.5x
P/Book0.9x
Beta0.64
Balance sheet & cash
Market capUS$24.2M
Total debtUS$6.1M
Free Cash FlowUS$2.5M
Debt / Equity22%
Profitability & ownership
ROE0.3%
ROA-3.0%
% insiders9.0%
% institutions34.1%
Last declaration on 29 December 2025
Declarations61 total
8,400 shares@ US$1.670348.2% of flowCommon StockSEC:0000905148-25-004488:0
Canonical exit: 23 Mar 2026 (T+90)
325 shares@ US$1.00181.2% of flowCommon StockSEC:0000905148-25-001216:0
Canonical exit: 13 Jul 2025 (T+90)
490 shares@ US$0.998532.2% of flowCommon StockSEC:0000905148-25-001215:0
Canonical exit: 13 Jul 2025 (T+90)
1,136 shares@ US$0.874767.8% of flowCommon StockSEC:0000905148-25-001190:0
Canonical exit: 8 Jul 2025 (T+90)
8,500 shares0Common StockSEC:0000905148-25-000740:0
8,500 shares0Common StockSEC:0000905148-25-000739:0
3,467 shares0Common StockSEC:0000905148-25-000737:0
8,500 shares0Common StockSEC:0000905148-25-000738:0
4,094 shares@ US$1.7341.1% of flowCommon StockSEC:0000905148-24-002363:0
Canonical exit: 20 Nov 2024 (T+90)
1,200 shares@ US$1.69880.3% of flowCommon StockSEC:0000905148-24-002340:0
Canonical exit: 19 Nov 2024 (T+90)
70,000 shares0Common StockSEC:0001209191-23-057725:0
877,192 shares@ US$2.289.1% of flowCommon Stock, par value $0.001 per share ("Common Stock")SEC:0001104659-23-119331:0
7,500 shares0Common StockSEC:0001209191-23-046702:0
312,525 shares@ US$3.67975.2% of flowCommon Stock, par value $0.001 per share ("Common Stock")SEC:0001104659-23-076387:0
1,010 shares0Common StockSEC:0001209191-23-027361:0
3,030 shares0Common StockSEC:0001209191-23-024388:0
50,000 shares0Common StockSEC:0001209191-23-024386:0
29,000 shares@ €1,250.380739.1% of flowSeries A Preferred Stock, par value $0.001 per shareSEC:0001104659-23-024323:0
2,400 shares0Common StockSEC:0001209191-23-005554:0
380 shares0Common StockSEC:0001209191-23-004871:0
29,000 shares@ €1,250.380739.1% of flowSeries A Preferred Stock, par value $0.001 per shareSEC:0001104659-23-000311:0
14,825 shares@ US$6.090.4% of flowCommon Stock, par value $0.001 per share ("Common Stock")SEC:0001104659-22-126117:0
Canonical exit: 9 Mar 2023 (T+90)
20,113 shares@ US$5.66250.5% of flowCommon Stock, par value $0.001 per share ("Common Stock")SEC:0001104659-22-125712:0
Canonical exit: 7 Mar 2023 (T+90)
3,167 shares0Common StockSEC:0001209191-22-060588:0
1,010 shares0Common StockSEC:0001209191-22-060587:0
25 of 61 declarations
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is a United States-based women’s health pharmaceutical company listed on the NASDAQ under the ticker TXMD. From an investor’s perspective, it is no longer a conventional fully integrated drug developer; the company now describes itself as a royalty company that licenses differentiated women’s health products in the United States and internationally through exclusive partners. Its strategic focus remains tightly concentrated on women’s health, particularly family planning, reproductive health, and menopause management. ([therapeuticsmd.com](https://www.therapeuticsmd.com/))
The company was founded around the idea of addressing underserved needs across the different stages of women’s lives. Over time, its business model has evolved materially, and the latest SEC filings show that the group is organized as a Nevada corporation with principal executive offices at 951 Yamato Road, Suite 220, Boca Raton, Florida. The 10-K also states that TherapeuticsMD operates in a fully remote environment and has subleased all of its Boca Raton premises following the shift toward a pharmaceutical royalty model. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0000025743/000121390026036515/ea0275992-10k_therape.htm))
Read moreShow less
TherapeuticsMD’s branded portfolio has included ANNOVERA®, BIJUVA® and IMVEXXY®, which are central to its women’s health platform. The company emphasizes that these products are licensed in the U.S. and the rest of the world to exclusive licensing partners, so the economic engine is based primarily on intellectual property, licensing arrangements, and partner commercialization rather than on a large in-house sales infrastructure. That structure can be capital-light relative to traditional pharma, but it also means the company is highly dependent on third parties for manufacturing, commercialization, reimbursement dynamics, and execution. ([therapeuticsmd.com](https://www.therapeuticsmd.com/))
In competitive terms, TXMD sits in a crowded segment where branded women’s health products compete against generics, alternative therapies, and larger pharmaceutical companies with deeper resources. The latest annual report highlights several key risk vectors: disputes with Mayne Pharma, the ability of licensees to commercialize licensed products successfully, regulatory and reimbursement pressure, and uncertainty around the company’s ability to continue as a going concern. These are important for equity investors because they indicate that the stock is driven as much by legal and financial developments as by product demand. ([ir.therapeuticsmd.com](https://ir.therapeuticsmd.com/news-releases/news-release-details/therapeuticsmd-announces-full-year-2025-financial-results))
Recent developments remain shaped by the transition story. On March 30, 2026, TherapeuticsMD reported full-year 2025 results, stating that license revenue increased year over year to $3.0 million while the net loss from continuing operations improved versus 2024. At the same time, management continued to flag substantial doubt about the company’s ability to continue as a going concern and ongoing litigation-related issues. For investors tracking U.S.-listed healthcare special situations, TXMD is best viewed as a small-cap royalty and litigation-sensitive name rather than a traditional growth pharma platform. ([ir.therapeuticsmd.com](https://ir.therapeuticsmd.com/news-releases/news-release-details/therapeuticsmd-announces-full-year-2025-financial-results))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
